Navigation Links
Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
Date:10/27/2010

NANJING, China, Oct. 27 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2010 on Thursday, November 11, 2010, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, November 11 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.6291International:

+1.617.213.8860North China toll-free:

10.800.152.1490South China toll-free:

10.800.130.0399China toll free / Netcom:

10.800.852.1490Hong Kong:

+852.3002.1672Please ask to be connected to Q3 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 18468376

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 16680817.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication, stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Frank ZhaoChief Financial OfficerSimcere Pharmaceutical GroupTel: +86-25-8556-6666 ext 8818In Beijing:Ruirui JiangBrunswick Group Tel: +86-10-6566-2256In the United States:Kate TellierBrunswick GroupTel: +1-212-333-3810In Hong Kong:Joseph Lo Chi-LunBrunswick GroupTel: +852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
2. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
3. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
5. Simceres Diosmectite API Passes EU-GMP Inspection
6. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
7. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
8. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
9. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
10. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
11. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Endo International plc (NASDAQ: ENDP ) ... , President, U.S. Branded Pharmaceuticals, has decided to ... of a successor. Mr. Lortie joined Endo in ... responsibility for all strategic, commercial and operational functions, ... commercial operations, managed markets, manufacturing, supply chain and ...
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... , May 5, 2016  Diagnostic imaging has ... due to concerns that these tests cause health care costs ... to imaging, as well as the adoption of ... of medical peripherals that help health care providers cut costs, ...  advanced medical imaging is a renowned authorized reseller of ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... ... Textile Exchange is excited to announce the release of the second ... is an important opportunity for interested parties to give input into the standard, and ... The RWS is intended to be a global benchmark for animal welfare and land ...
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is proud ... cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, which ... American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrations ...
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers announced today that ... eye center will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser ... the full-service facility to ensure that patients continue to receive the highest quality of ...
(Date:5/5/2016)... ... May 05, 2016 , ... Spring Fertility , ... IVF and with egg freezing, today announced the grand opening of its first ... fertility care, Spring Fertility offers both fertility preservation (egg, sperm, embryo, and testicular ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
Breaking Medicine News(10 mins):